Cover Image
市場調查報告書

尋常痤瘡 : 開發平台分析

Acne Vulgaris - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 232807
出版日期 內容資訊 英文 200 Pages
訂單完成後即時交付
價格
Back to Top
尋常痤瘡 : 開發平台分析 Acne Vulgaris - Pipeline Review, H2 2016
出版日期: 2016年10月26日 內容資訊: 英文 200 Pages
簡介

所謂尋常性痤瘡是指臉上及軀幹上的囊脂肪腺小胞異常,其分泌物引起發炎,造成膿皰、結痂、囊胞等,甚至疼痛。青年期、髮膠、油性化妝品、頭盔皮帶的摩擦等運動用品、皮膚阻塞、部分處方藥(鋰、異煙肼、苯妥英鈉、皮質類固醇等)是致病原因,治療方法有使用抗生素、避孕藥、類維生素A等。

本報告涵括全球尋常痤瘡治療藥的開發平台,提供您目前開發平台狀況和最新趨勢,藥物簡介,主要企業及開發中的產品檢討等,為您概述為以下內容。

目錄

簡介

  • 分析範圍

尋常痤瘡概要

治療藥的開發

  • 尋常痤瘡開發中產品:概要
  • 尋常痤瘡開發中產品:比較分析

尋常痤瘡:正在開發的治療藥:各企業

尋常痤瘡:正在開發的治療藥:大學·研究機關別

尋常痤瘡:開發中產品概況

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

尋常痤瘡:開發中的產品:各企業

尋常痤瘡:開發中的產品:大學·研究機關別

尋常痤瘡:治療藥開發作的企業

  • 3SBio Inc.
  • Advancell
  • Allergan Plc
  • Almirall, S.A.
  • Biomar Microbial Technologies
  • Braintree Laboratories, Inc.
  • Brickell Biotech, Inc.
  • Celtaxsys, Inc.
  • Cosmo Pharmaceuticals S.p.A
  • Delenex Therapeutics AG
  • Deltanoid Pharmaceuticals Inc.
  • DermaXon, LLC
  • Dermira Inc.
  • ELORAC, Inc.
  • Ensol Biosciences Inc.
  • Foamix Pharmaceuticals Ltd.
  • Galderma S.A.
  • GlaxoSmithKline Plc
  • Helix BioMedix, Inc.
  • Hovione FarmaCiencia SA
  • Lee's Pharmaceutical Holdings Limited
  • Maruho
  • Novabiotics Limited
  • Novan, Inc.
  • OrigImm e.U.
  • Paratek Pharmaceuticals, Inc.
  • Phosphagenics Limited
  • Photocure ASA
  • Promius Pharma, LLC
  • Provectus Biopharmaceuticals, Inc.
  • RestorGenex Corporation
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
  • SkyePharma Plc
  • Telesso Technologies Limited
  • Thesan Pharmaceuticals, Inc.
  • 富山化學工業
  • Valeant Pharmaceuticals International, Inc.
  • Venn Life Sciences Holdings Plc
  • Vyome Biosciences Private Limited
  • Xenon Pharmaceuticals Inc.

尋常痤瘡:治療藥的評估

  • 單劑治療藥
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • (adapalene + benzoyl peroxide)
  • (adapalene + clindamycin hydrochloride)
  • (clindamycin phosphate + tretinoin)
  • acebilustat
  • Aczone X
  • AD-037
  • aminolevulinic acid hydrochloride
  • ANs-29
  • AQ-401
  • B-244
  • BBI-3000
  • becocalcidiol
  • benzoyl peroxide
  • benzoyl peroxide
  • BLI-1100
  • CB-0301
  • CB-0604
  • DFD-10
  • DLX-2323
  • DLX-2681
  • DRM-01
  • Drugs for Acne
  • DX-0385
  • E-10215
  • finasteride
  • FMX-101
  • GSK-1940029
  • HB-1345
  • Hesed-4000
  • IB-07A037
  • IDP-120
  • IDP-121
  • IDP-123
  • methyl aminolevulinate hydrochloride
  • minocycline
  • minocycline
  • MTC-896
  • NAI-003
  • NVN-1000
  • omiganan pentahydrochloride
  • onabotulinumtoxin A
  • ozenoxacin
  • Peptide to Disrupt Bacterial Cell Membrane and Cell Wall for Acne And Skin Cancer
  • PH-10
  • RES-440
  • sarecycline hydrochloride
  • SKP-026
  • Small Molecule for Acne and Skin Inflammation
  • SYN-1113
  • Synthetic Peptide for Acne Vulgaris
  • Synthetic Peptides to Inhibit Kallikrein for Immunology, Dermatological and Genetic Disorders
  • tretinoin
  • trifarotene
  • Vaccine for Acne Vulgaris
  • Vaccine for Acne Vulgaris
  • VB-1953
  • XEN-801

最新的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發里程碑

  • 關注的新聞·新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8569IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acne Vulgaris - Pipeline Review, H2 2016, provides an overview of the Acne Vulgaris (Dermatology) pipeline landscape.

Acne vulgaris is a chronic skin disease involving blockage and inflammation of pilosebaceous follicles. Symptoms include crusting of skin bumps, cysts, papules (small red bumps), scarring of the skin and redness around the skin eruptions. The predisposing factors include adolescence, hair gels or oil-based cosmetics, sports equipment such as helmet straps rubbing and occluding skin. Treatment includes antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acne Vulgaris - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Acne Vulgaris (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acne Vulgaris (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Acne Vulgaris and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 8, 22, 9, 2, 17 and 3 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively for Acne Vulgaris.

Acne Vulgaris (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Acne Vulgaris (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Acne Vulgaris (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Acne Vulgaris (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Acne Vulgaris (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Acne Vulgaris (Dermatology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Acne Vulgaris (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Acne Vulgaris (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Acne Vulgaris Overview
  • Therapeutics Development
    • Pipeline Products for Acne Vulgaris - Overview
    • Pipeline Products for Acne Vulgaris - Comparative Analysis
  • Acne Vulgaris - Therapeutics under Development by Companies
  • Acne Vulgaris - Therapeutics under Investigation by Universities/Institutes
  • Acne Vulgaris - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Acne Vulgaris - Products under Development by Companies
  • Acne Vulgaris - Products under Investigation by Universities/Institutes
  • Acne Vulgaris - Companies Involved in Therapeutics Development
    • 3SBio Inc.
    • Allergan Plc
    • Almirall, S.A.
    • Antibiotx ApS
    • Biomar Microbial Technologies
    • BiopharmX, Inc.
    • Braintree Laboratories, Inc.
    • Brickell Biotech, Inc.
    • Cell Medica Limited
    • Cellceutix Corporation
    • Celtaxsys, Inc.
    • Common Pharma Inc
    • Cutanea Life Sciences Inc
    • DermaXon, LLC
    • Dermira Inc.
    • Diffusion Pharmaceuticals Inc.
    • ELORAC, Inc.
    • Ensol Biosciences Inc.
    • Foamix Pharmaceuticals Ltd.
    • Galderma S.A.
    • GlaxoSmithKline Plc
    • Helix BioMedix, Inc.
    • Hovione FarmaCiencia SA
    • Lee's Pharmaceutical Holdings Limited
    • LEO Pharma A/S
    • Novabiotics Limited
    • Novan, Inc.
    • Paratek Pharmaceuticals, Inc.
    • Pfizer Inc.
    • Phosphagenics Limited
    • Photocure ASA
    • Promius Pharma, LLC
    • Provectus Biopharmaceuticals, Inc.
    • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
    • Sol-Gel Technologies Ltd.
    • Sun Pharma Advanced Research Company Ltd.
    • Telesso Technologies Limited
    • Thesan Pharmaceuticals, Inc.
    • Valeant Pharmaceuticals International, Inc.
    • Vectura Group Plc
    • Vyome Biosciences Private Limited
    • XBiotech Inc
    • Xenon Pharmaceuticals Inc.
  • Acne Vulgaris - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (adapalene + clindamycin hydrochloride) - Drug Profile
    • (benzoyl peroxide + tretinoin) - Drug Profile
    • (clindamycin phosphate + tretinoin) - Drug Profile
    • A-3APO - Drug Profile
    • acebilustat - Drug Profile
    • Aczone Combo - Drug Profile
    • Aczone X - Drug Profile
    • aminolevulinic acid hydrochloride - Drug Profile
    • AQ-401 - Drug Profile
    • ATx-202 - Drug Profile
    • B-244 - Drug Profile
    • BBI-3000 - Drug Profile
    • benzoyl peroxide - Drug Profile
    • BLI-1100 - Drug Profile
    • botulinum toxinA - Drug Profile
    • brilacidin tetrahydrochloride - Drug Profile
    • CB-0301 - Drug Profile
    • CB-0601 - Drug Profile
    • CLS-007 - Drug Profile
    • dapsone - Drug Profile
    • DFD-10 - Drug Profile
    • DLX-2323 - Drug Profile
    • DLX-2681 - Drug Profile
    • DMT-210 - Drug Profile
    • DRM-01 - Drug Profile
    • DX-0385 - Drug Profile
    • E-10215 - Drug Profile
    • finasteride - Drug Profile
    • FMX-101 - Drug Profile
    • GSK-1940029 - Drug Profile
    • HB-1345 - Drug Profile
    • Hesed-4000 - Drug Profile
    • IB-07A037 - Drug Profile
    • IDP-120 - Drug Profile
    • IDP-121 - Drug Profile
    • IDP-123 - Drug Profile
    • IDP-126 - Drug Profile
    • IDP-129 - Drug Profile
    • IDP-130 - Drug Profile
    • ivermectin - Drug Profile
    • LEO-43204 - Drug Profile
    • LTA-001 - Drug Profile
    • methyl aminolevulinate hydrochloride - Drug Profile
    • minocycline - Drug Profile
    • minocycline - Drug Profile
    • minocycline hydrochloride - Drug Profile
    • MTC-896 - Drug Profile
    • omiganan pentahydrochloride - Drug Profile
    • Peptide to Disrupt Bacterial Cell Membrane and Cell Wall for Acne And Skin Cancer - Drug Profile
    • PF-06423264 - Drug Profile
    • PH-10 - Drug Profile
    • RA-18C3 - Drug Profile
    • RES-440 - Drug Profile
    • sarecycline hydrochloride - Drug Profile
    • SB-204 - Drug Profile
    • SKP-026 - Drug Profile
    • Small Molecule for Acne and Skin Inflammation - Drug Profile
    • Small Molecules for Acne Vulgaris - Drug Profile
    • Synthetic Peptide for Acne Vulgaris - Drug Profile
    • Synthetic Peptide to Inhibit SREBP1 for Acne, Amyotrophic Lateral Sclerosis and Stroke - Drug Profile
    • tazarotene - Drug Profile
    • tretinoin - Drug Profile
    • tretinoin - Drug Profile
    • trifarotene - Drug Profile
    • TSN-2898 - Drug Profile
    • Vaccine for Acne Vulgaris - Drug Profile
    • VB-1953 - Drug Profile
    • XEN-801 - Drug Profile
  • Acne Vulgaris - Dormant Projects
  • Acne Vulgaris - Discontinued Products
  • Acne Vulgaris - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Acne Vulgaris, H2 2016
  • Number of Products under Development for Acne Vulgaris - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Acne Vulgaris - Pipeline by 3SBio Inc., H2 2016
  • Acne Vulgaris - Pipeline by Allergan Plc, H2 2016
  • Acne Vulgaris - Pipeline by Almirall, S.A., H2 2016
  • Acne Vulgaris - Pipeline by Antibiotx ApS, H2 2016
  • Acne Vulgaris - Pipeline by Biomar Microbial Technologies, H2 2016
  • Acne Vulgaris - Pipeline by BiopharmX, Inc., H2 2016
  • Acne Vulgaris - Pipeline by Braintree Laboratories, Inc., H2 2016
  • Acne Vulgaris - Pipeline by Brickell Biotech, Inc., H2 2016
  • Acne Vulgaris - Pipeline by Cell Medica Limited, H2 2016
  • Acne Vulgaris - Pipeline by Cellceutix Corporation, H2 2016
  • Acne Vulgaris - Pipeline by Celtaxsys, Inc., H2 2016
  • Acne Vulgaris - Pipeline by Common Pharma Inc, H2 2016
  • Acne Vulgaris - Pipeline by Cutanea Life Sciences Inc, H2 2016
  • Acne Vulgaris - Pipeline by DermaXon, LLC, H2 2016
  • Acne Vulgaris - Pipeline by Dermira Inc., H2 2016
  • Acne Vulgaris - Pipeline by Diffusion Pharmaceuticals Inc., H2 2016
  • Acne Vulgaris - Pipeline by ELORAC, Inc., H2 2016
  • Acne Vulgaris - Pipeline by Ensol Biosciences Inc., H2 2016
  • Acne Vulgaris - Pipeline by Foamix Pharmaceuticals Ltd., H2 2016
  • Acne Vulgaris - Pipeline by Galderma S.A., H2 2016
  • Acne Vulgaris - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Acne Vulgaris - Pipeline by Helix BioMedix, Inc., H2 2016
  • Acne Vulgaris - Pipeline by Hovione FarmaCiencia SA, H2 2016
  • Acne Vulgaris - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016
  • Acne Vulgaris - Pipeline by LEO Pharma A/S, H2 2016
  • Acne Vulgaris - Pipeline by Novabiotics Limited, H2 2016
  • Acne Vulgaris - Pipeline by Novan, Inc., H2 2016
  • Acne Vulgaris - Pipeline by Paratek Pharmaceuticals, Inc., H2 2016
  • Acne Vulgaris - Pipeline by Pfizer Inc., H2 2016
  • Acne Vulgaris - Pipeline by Phosphagenics Limited, H2 2016
  • Acne Vulgaris - Pipeline by Photocure ASA, H2 2016
  • Acne Vulgaris - Pipeline by Promius Pharma, LLC, H2 2016
  • Acne Vulgaris - Pipeline by Provectus Biopharmaceuticals, Inc., H2 2016
  • Acne Vulgaris - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H2 2016
  • Acne Vulgaris - Pipeline by Sol-Gel Technologies Ltd., H2 2016
  • Acne Vulgaris - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2016
  • Acne Vulgaris - Pipeline by Telesso Technologies Limited, H2 2016
  • Acne Vulgaris - Pipeline by Thesan Pharmaceuticals, Inc., H2 2016
  • Acne Vulgaris - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2016
  • Acne Vulgaris - Pipeline by Vectura Group Plc, H2 2016
  • Acne Vulgaris - Pipeline by Vyome Biosciences Private Limited, H2 2016
  • Acne Vulgaris - Pipeline by XBiotech Inc, H2 2016
  • Acne Vulgaris - Pipeline by Xenon Pharmaceuticals Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Acne Vulgaris - Dormant Projects, H2 2016
  • Acne Vulgaris - Dormant Projects (Contd..1), H2 2016
  • Acne Vulgaris - Dormant Projects (Contd..2), H2 2016
  • Acne Vulgaris - Dormant Projects (Contd..3), H2 2016
  • Acne Vulgaris - Dormant Projects (Contd..4), H2 2016
  • Acne Vulgaris - Dormant Projects (Contd..5), H2 2016
  • Acne Vulgaris - Dormant Projects (Contd..6), H2 2016
  • Acne Vulgaris - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Acne Vulgaris, H2 2016
  • Number of Products under Development for Acne Vulgaris - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top